Chaos Theory and Fractals: A forgotten name in Healthcare
About the Tickers: Corbus Pharmaceuticals Holdings, Inc. 
CRBP is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform. Phase 3 trial of Lenabasum in Systemic Sclerosis was unsuccessful last year. Currently, a phase 3 trial in Dermatomyositis is scheduled to read out top line results by Q2 2021.
The Chart: Appears similar to Cassava
SAVA which also saw setbacks and plunged to about $1 a share. Can we use fractals and chaos theory to predict the price of CRBP stock in the near term? Possibly.
Corbus Pharmaceuticals (CRBP) is currently trading at about $2 a share. Cassava Sciences (SAVA) is trading at about $54 a share.
CRBP is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform. Phase 3 trial of Lenabasum in Systemic Sclerosis was unsuccessful last year. Currently, a phase 3 trial in Dermatomyositis is scheduled to read out top line results by Q2 2021. The Chart: Appears similar to Cassava
SAVA which also saw setbacks and plunged to about $1 a share. Can we use fractals and chaos theory to predict the price of CRBP stock in the near term? Possibly.Corbus Pharmaceuticals (
CRBP) is currently trading at about $2 a share. Cassava Sciences (SAVA) is trading at about $54 a share. 
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.